Crolom
| Crolom | |
|---|---|
| DOSAGE | 1-2 gtt 4-6/day |
| GENERIC | cromolyn sodium 4.0% |
| SIZE | 10mL, 15mL |
| INDICATIONS | Cromolyn Sodium Ophthalmic Solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |
| MECHANISM OF ACTION | Mast Cell Stabilizer (1st generation) |
| MICROBIOLOGY | Cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. Another study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate. Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity. |
| CONTRAINDICATIONS & WARNINGS | Cromolyn Sodium Ophthalmic Solution is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients. |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients below the age of 4 years have not been established. |
| PREGNANCY | Category B Teratogenic effects: There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. |
| NOTE | Consider a combination antihistamine / mast cell stabilizer. |